BIOMAT Database Logo BIOMAT Database Logo

Use of anemic piglet to assess bioavailability of iron from oral iron preparations. 1977

A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free

Except for methods using long-lived iron isotopes, there are no reliable means for assessing the bioavilability of iron from oral preparations in human subjects. Use of the anemic piglet as an alternative means was studied. When piglets were made anemic on a commercial milk diet and then dosed with solutions of 1, 2, and 5 mg/kg of ferrous sulfate/day, a dose-related recovery of hematocrit and hemoglobin levels resulted. The most sensitive dose range for use in a bioavailability study of iron was between 1 and 2 mg of iron/kg/day when using these parameters. A study carried out using this method indicated that the iron from a delayed-release capsule and from a ferrous sulfate solution was equally bioavailable. Hemoglobin and hematocrit recovery rates of the anemic piglet were shown to be reliable and sensitive indicators of the bioavailability of iron from various iron dosage forms.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008297 Male Males
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D006452 Hemoglobinometry Measurement of hemoglobin concentration in blood. Hemoglobinometries
D000747 Anemia, Hypochromic Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393) Chlorosis,Anemias, Hypochromic,Chloroses,Hypochromic Anemia,Hypochromic Anemias
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
[Bioavailability of oral iron preparations].
November 1979, Deutsche medizinische Wochenschrift (1946),
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
[Bioavailability of oral iron preparations].
August 1979, Deutsche medizinische Wochenschrift (1946),
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
[Bioavailability of oral iron preparations].
August 1979, Deutsche medizinische Wochenschrift (1946),
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
Study of bioavailability of oral iron preparations.
April 1976, Journal of postgraduate medicine,
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
[Bioavailability of various iron preparations following oral medication].
December 1980, Fortschritte der Medizin,
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
[Bioavailability of levomycetin preparations for oral use].
October 1983, Antibiotiki,
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
Use of HemoQuant assays to assess the effect of oral iron preparations on stool hemoccult tests.
October 1991, The American journal of gastroenterology,
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
Evaluation of iron bioavailability from bonito dark muscle using anemic rats.
July 2003, Journal of agricultural and food chemistry,
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
Bioavailability of Microencapsulated Iron from Fortified Bread Assessed Using Piglet Model.
March 2017, Nutrients,
A P Intoccia, and S S Walkenstein, and R W Wittendorf, and R C Hoppe, and S M Free
Effect of coprophagy on bioavailability of iron from plant foods fed to anemic rats.
April 1992, Plant foods for human nutrition (Dordrecht, Netherlands),
Copied contents to your clipboard!